On July 9, 2026, the National Health Commission, in collaboration with multiple government departments, released the *National Essential Medicines List (2026 Edition)*, which includes a total of 794 medicines.¹ Among them, Bayful (moxifloxacin hydrochloride tablets/sodium chloride injection) was successfully retained in the new edition of the National Essential Medicines List due to its outstanding clinical value in the field of anti-infective therapy. A 24-Year Journey in China: From Market Launch to Continued Recognition in the Essential Medicines List Over the past 24 years, Bayfulu® has served numerous patients with infectious diseases in China. In 2018, moxifloxacin was first included in the *National Essential Medicines List*, and its continued inclusion in the 2026 edition of the list

Recently, Hangzhou Shanze Biopharmaceutical Co., Ltd. and its parent company, Ascenda Pte. Ltd. (hereinafter referred to as “Shanze Biopharmaceutical”), formally signed a strategic cooperation agreement on import distribution with Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. (hereinafter referred to as “Shangyao Keyuan Trading”). The two parties announced that they will engage in in-depth cooperation centered on Shanze Bio’s flagship product—Moxifloxacin Hydrochloride and Sodium Chloride Injection (brand name: Baifulu®). Bai Fu Le® is a fluoroquinolone antibiotic that was first approved for marketing in Europe and the United States in 1999 and entered the Chinese market in 2002. To date, it has served over

(Singapore/Shanghai | February 2, 2026) Sequoia China announced that on February 2, 2026, it officially completed the global acquisition of the business and assets related to moxifloxacin (brand name: Baifulu®/ Avelox®), and has established Hangzhou Shanze Biopharmaceutical Co., Ltd. (hereinafter “Shanze Biopharm”), an innovative biopharmaceutical company focused on anti-infectives, respiratory, and critical care, with its parent company, Ascenda Pte. Ltd., responsible for the operations of this business. Pursuant to the agreement, Shanze Bio and its parent company, Ascenda Pte. Lt